EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate, and when can generic versions of Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate launch?
Efidac 24 Pseudoephedrine Hydrochloride/brompheniramine Maleate is a drug marketed by Alza and is included in one NDA.
The generic ingredient in EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE is brompheniramine maleate; pseudoephedrine hydrochloride. There are twenty-one drug master file entries for this compound. Additional details are available on the brompheniramine maleate; pseudoephedrine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE?
- What are the global sales for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE?
- What is Average Wholesale Price for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE?
Summary for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE at DailyMed |
US Patents and Regulatory Information for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alza | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE | brompheniramine maleate; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019672-001 | Mar 29, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alza | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE | brompheniramine maleate; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019672-001 | Mar 29, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Alza | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE | brompheniramine maleate; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019672-001 | Mar 29, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Alza | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE | brompheniramine maleate; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019672-001 | Mar 29, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Alza | EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE | brompheniramine maleate; pseudoephedrine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019672-001 | Mar 29, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
See the table below for patents covering EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 9203735 | UNA FORMA DE DOSIS MEJORADA PARA SUMINISTRAR UNA DROGA O UN AGENTE TERAPEUTICO A UN AMBIENTE DE USO. | ⤷ Sign Up |
| Japan | S62221625 | THERAPEUTICAL MEDICINE CONTAINING PSEUDOEPHEDRINE AND BROMPHENIRAMINE | ⤷ Sign Up |
| Netherlands | 192720 | ⤷ Sign Up | |
| Ireland | 840156 | ⤷ Sign Up | |
| Germany | 3769307 | ⤷ Sign Up | |
| South Korea | 950001011 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
